OPKO Health (OPK) moved into focus after its Q2 2026 earnings report and guidance, which showed revenue of US$163.58 million and a sharply lower net loss compared with the prior year period.

OPKO Health shares have been volatile around the earnings release, with the 1-day share price return falling 17.27% after hitting a new 52-week high. However, the 90-day share price return of 24.09% and 1-year total shareholder return of 6.64% suggest momentum has been building from a low base despite a weaker 5-year total shareholder return.

If this kind of turnaround story has your attention, it can be worth scanning for other healthcare stocks with AI exposure using our curated list of 41 healthcare AI stocks

OPKO Health now appears to be operating more as a functioning healthcare platform than a distressed story, yet the stock just swung from a fresh 52-week high to a sharp pullback. Do those new fundamentals line up with today’s share price?

Most Popular Narrative: 69% Undervalued

OPKO Health closed at $1.37 compared with a widely followed fair value estimate of $4.38. That gap reflects a very specific growth and margin story.

The sale of BioReference's oncology and related clinical testing assets to Labcorp is expected to sharpen OPKO Health's focus on its core testing business, drive significant cost savings, and support the Diagnostics segment's transition to cash flow positive and profitability in 2025, providing margin expansion and stabilizing earnings.

Curious what has to happen for OPKO Health to reach that higher fair value. The narrative leans heavily on gradual revenue gains, margin repair, and a richer earnings multiple.

Result: Fair Value of $4.38 (UNDERVALUED)

However, OPKO Health still carries clear risks, including ongoing net losses and heavy R&D spending, as well as competition that could limit uptake of its key products.

Another View on OPKO Health’s Valuation

The fair value narrative for OPKO Health points to a large gap between the $1.37 share price and a $4.38 estimate. Yet on a simple P/S basis the stock looks expensive, trading at 1.7x versus a fair ratio of 0.6x, the US Healthcare average of 1.5x, and a 1.4x peer average. That kind of premium can limit upside if growth or margins do not move as hoped, so which signal do you trust more right now?

To see how this pricing gap plays out in practice and what the numbers imply in different scenarios, take a closer look at the valuation breakdown using our P/S workup, then compare it with your own expectations for OPKO Health, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

OPKO Health’s mixed signals on valuation and fundamentals can split opinion, so it makes sense to check the data directly and consider acting early if needed. A practical place to start is by reviewing the 3 important warning signs.

Looking for more investment ideas beyond OPKO Health?

If OPKO Health has you thinking more broadly about opportunities, do not stop here. Use the screener to uncover other stocks that fit your style before the market moves.

• Target potential turnaround opportunities by scanning 20 elite penny stocks with strong financials that combine smaller market caps with stronger financial profiles than many peers.
• Zero in on value by reviewing 48 high quality undervalued stocks that pair solid fundamentals with prices that sit below fair value estimates.
• Focus on resilience by checking 85 resilient stocks with low risk scores that score well on balance sheet strength and overall risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.